Literature DB >> 24360910

The cytokine and endocannabinoid systems are co-regulated by NF-κB p65/RelA in cell culture and transgenic mouse models of Huntington's disease and in striatal tissue from Huntington's disease patients.

Robert B Laprairie1, Jordan R Warford2, Sarah Hutchings3, George S Robertson4, Melanie E M Kelly5, Eileen M Denovan-Wright6.   

Abstract

Transcriptional dysregulation is a major pathological feature of Huntington's disease (HD). The goal of this study was to understand how p65/RelA co-regulated genes, specifically those of the cytokine and endocannabinoid systems, were affected in HD. p65/RelA levels were lower in human HD tissue and R6/2 HD mice, as were the levels of the type 1 cannabinoid receptor (CB1), IL-1β, IL-8, CCL5, GM-CSF, MIP-1β, and TNFα, all of which may be regulated by p65/RelA. Activation of p65/RelA restored CB1 and CCL5 expression in STHdh cell models of HD. Therefore, p65/RelA activation may normalize the expression of some genes in HD.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cannabinoid; Cytokine; Huntington's disease; NF-κB p65/RelA; Neuroinflammation

Mesh:

Substances:

Year:  2013        PMID: 24360910     DOI: 10.1016/j.jneuroim.2013.12.008

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  8 in total

1.  Huntington's disease pattern of transcriptional dysregulation in the absence of mutant huntingtin is produced by knockout of neuronal GLT-1.

Authors:  Robert B Laprairie; Geraldine T Petr; Yan Sun; Kathryn D Fischer; Eileen M Denovan-Wright; Paul A Rosenberg
Journal:  Neurochem Int       Date:  2018-04-27       Impact factor: 3.921

2.  Positive allosteric modulation of the type 1 cannabinoid receptor reduces the signs and symptoms of Huntington's disease in the R6/2 mouse model.

Authors:  Robert B Laprairie; Amina M Bagher; Jillian L Rourke; Adel Zrein; Elizabeth A Cairns; Melanie E M Kelly; Christopher J Sinal; Pushkar M Kulkarni; Ganesh A Thakur; Eileen M Denovan-Wright
Journal:  Neuropharmacology       Date:  2019-03-30       Impact factor: 5.250

3.  Ginsenoside Rg1 exerts neuroprotective effects in 3-nitropronpionic acid-induced mouse model of Huntington's disease via suppressing MAPKs and NF-κB pathways in the striatum.

Authors:  Xiong Yang; Shi-Feng Chu; Zhen-Zhen Wang; Fang-Fang Li; Yu-He Yuan; Nai-Hong Chen
Journal:  Acta Pharmacol Sin       Date:  2020-11-19       Impact factor: 7.169

4.  Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor.

Authors:  R B Laprairie; A M Bagher; M E M Kelly; E M Denovan-Wright
Journal:  Br J Pharmacol       Date:  2015-10-13       Impact factor: 8.739

5.  PIAS1 Regulates Mutant Huntingtin Accumulation and Huntington's Disease-Associated Phenotypes In Vivo.

Authors:  Joseph Ochaba; Alex Mas Monteys; Jacqueline G O'Rourke; Jack C Reidling; Joan S Steffan; Beverly L Davidson; Leslie M Thompson
Journal:  Neuron       Date:  2016-04-14       Impact factor: 17.173

6.  Systems approach to the study of brain damage in the very preterm newborn.

Authors:  Alan Leviton; Pierre Gressens; Olaf Wolkenhauer; Olaf Dammann
Journal:  Front Syst Neurosci       Date:  2015-04-14

7.  Components of the endocannabinoid and dopamine systems are dysregulated in Huntington's disease: analysis of publicly available microarray datasets.

Authors:  Robert B Laprairie; Amina M Bagher; Sophie V Precious; Eileen M Denovan-Wright
Journal:  Pharmacol Res Perspect       Date:  2015-01-05

Review 8.  Transcriptional Dysregulation and Post-translational Modifications in Polyglutamine Diseases: From Pathogenesis to Potential Therapeutic Strategies.

Authors:  Chunchen Xiang; Shun Zhang; Xiaoyu Dong; Shuang Ma; Shuyan Cong
Journal:  Front Mol Neurosci       Date:  2018-05-15       Impact factor: 5.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.